phenytoin has been researched along with Cerebral Ischemia in 38 studies
Excerpt | Relevance | Reference |
---|---|---|
"Current guidelines recommend against the use of phenytoin following aneurysmal subarachnoid hemorrhage (aSAH) but consider other anticonvulsants, such as levetiracetam, acceptable." | 7.80 | Incidence of delayed seizures, delayed cerebral ischemia and poor outcome with the use of levetiracetam versus phenytoin after aneurysmal subarachnoid hemorrhage. ( Fletcher, JJ; Karamchandani, RR; Pandey, AS; Rajajee, V, 2014) |
"Topiramate, a structurally novel anticonvulsant, and phenytoin were evaluated in a rat model of ischemia-induced epilepsy." | 7.69 | Anticonvulsant activity of topiramate and phenytoin in a rat model of ischemia-induced epilepsy. ( Edmonds, HL; Jiang, YD; Shank, RP; Zhang, PY, 1996) |
" The present experiments compared the noncompetitive N-methyl-D-aspartate antagonists phencyclidine and MK-801 with the anticonvulsant phenytoin in a model of focal brain ischemia." | 7.68 | Comparison of phenytoin with noncompetitive N-methyl-D-aspartate antagonists in a model of focal brain ischemia in rat. ( Boxer, PA; Cordon, JJ; Mann, ME; Marcoux, FW; Rock, DM; Rodolosi, LC; Taylor, CP; Vartanian, MG, 1990) |
" The purpose of the present experiment is to study the therapeutic effect of phenytoin on cerebral ischemia and confirm whether the effectiveness of phenytoin could be enhanced by combination of free radical scavengers such as mannitol and vitamin E." | 7.67 | [Protective effect of phenytoin and its enhanced action by combined administration of mannitol and vitamin E in cerebral ischemia]. ( Abiko, H; Mizoi, K; Oba, M; Suzuki, J; Yoshimoto, T, 1986) |
"To study the protective effect of phenytoin on postischemic brain damage, total cerebral ischemia was produced for 8-12 min (aortic occlusion balloon catheter method) in 36 adult mongrel dogs." | 7.66 | Effects of phenytoin on regional cerebral blood flow, electroencephalogram, and electrolyte contents in cerebral blood and cerebral cortex following total cerebral ischemia in dogs. ( Fukuda, A; Ihara, N; Ikeda, H; Kohama, A; Tabuse, H; Tanabe, J, 1983) |
"Current guidelines recommend against the use of phenytoin following aneurysmal subarachnoid hemorrhage (aSAH) but consider other anticonvulsants, such as levetiracetam, acceptable." | 3.80 | Incidence of delayed seizures, delayed cerebral ischemia and poor outcome with the use of levetiracetam versus phenytoin after aneurysmal subarachnoid hemorrhage. ( Fletcher, JJ; Karamchandani, RR; Pandey, AS; Rajajee, V, 2014) |
"Na(+)K(+)-ATPase activity, water content, and Na+/K+ concentrations in the parietal cortex were measured in untreated and phenytoin-treated rats following global cerebral ischemia." | 3.69 | Effect of phenytoin on cortical Na(+)-K(+)-ATPase activity in global ischemic rat brain. ( Imaizumi, S; Kinouchi, H; Kurosawa, K; Yoshimoto, T, 1995) |
"Topiramate, a structurally novel anticonvulsant, and phenytoin were evaluated in a rat model of ischemia-induced epilepsy." | 3.69 | Anticonvulsant activity of topiramate and phenytoin in a rat model of ischemia-induced epilepsy. ( Edmonds, HL; Jiang, YD; Shank, RP; Zhang, PY, 1996) |
" The present experiments compared the noncompetitive N-methyl-D-aspartate antagonists phencyclidine and MK-801 with the anticonvulsant phenytoin in a model of focal brain ischemia." | 3.68 | Comparison of phenytoin with noncompetitive N-methyl-D-aspartate antagonists in a model of focal brain ischemia in rat. ( Boxer, PA; Cordon, JJ; Mann, ME; Marcoux, FW; Rock, DM; Rodolosi, LC; Taylor, CP; Vartanian, MG, 1990) |
" The purpose of the present experiment is to study the therapeutic effect of phenytoin on cerebral ischemia and confirm whether the effectiveness of phenytoin could be enhanced by combination of free radical scavengers such as mannitol and vitamin E." | 3.67 | [Protective effect of phenytoin and its enhanced action by combined administration of mannitol and vitamin E in cerebral ischemia]. ( Abiko, H; Mizoi, K; Oba, M; Suzuki, J; Yoshimoto, T, 1986) |
"To study the protective effect of phenytoin on postischemic brain damage, total cerebral ischemia was produced for 8-12 min (aortic occlusion balloon catheter method) in 36 adult mongrel dogs." | 3.66 | Effects of phenytoin on regional cerebral blood flow, electroencephalogram, and electrolyte contents in cerebral blood and cerebral cortex following total cerebral ischemia in dogs. ( Fukuda, A; Ihara, N; Ikeda, H; Kohama, A; Tabuse, H; Tanabe, J, 1983) |
"When phenytoin was discontinued, valproate levels increased, and he progressively improved." | 1.30 | Exceptionally long absence status: multifactorial etiology, drug interactions and complications. ( Andermann, F; Bastos, A; D'Agostino, MD; Dubeau, F; Fedi, M, 1999) |
"In complete global ischemia (cardiac arrest) reperfusion is characterized by an immediate reactive hyperemia followed within 20-30 min by a delayed hypoperfusion state." | 1.29 | [Cerebral protection]. ( Cattaneo, AD, 1993) |
"When phenytoin was administered immediately after the hypoxia, there was no difference between vehicle-injected controls and phenytoin-treated pups." | 1.29 | Phenytoin reduces neonatal hypoxic-ischemic brain damage in rats. ( Hamada, Y; Hattori, H; Hayakawa, T; Maihara, T; Mikawa, H, 1994) |
"The duration of the vegetative state was 12 days, 15 days or about 4 months until death and was associated with corresponding stages of generalized ischemic brain damage." | 1.29 | Relationship between ischemic damage and concentrations of phenytoin and phenobarbital in the brain cortex of epileptic patients in vegetative state at death. ( Jürgens, U; Lahl, R; May, T; Rambeck, B; Schnabel, R, 1996) |
"With regard to the degree of brain swelling, a similar dose-related suppressive effect was seen in the phenytoin-treated groups." | 1.27 | Protective effect of phenytoin and its enhanced action by combined administration with mannitol and vitamin E in cerebral ischaemia. ( Abiko, H; Mizoi, K; Oba, M; Suzuki, J; Yoshimoto, T, 1987) |
"Mannitol treatment had no protective effect, but phenytoin, vitamin E and dexamethasone had clear dose-dependent effect." | 1.27 | [Protective effect of various agents against ischemic neuronal damage in guinea pig hippocampal neurons studied in vitro]. ( Amagasa, M; Mizoi, K; Suzuki, J; Yoshimoto, T, 1988) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 14 (36.84) | 18.7374 |
1990's | 19 (50.00) | 18.2507 |
2000's | 2 (5.26) | 29.6817 |
2010's | 3 (7.89) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Sathishkumar, D | 1 |
George, R | 1 |
Irodi, A | 1 |
Thomas, M | 1 |
Karamchandani, RR | 1 |
Fletcher, JJ | 1 |
Pandey, AS | 1 |
Rajajee, V | 1 |
Maconochie, I | 1 |
Ross, M | 1 |
Tanabe, M | 1 |
Umeda, M | 1 |
Honda, M | 1 |
Ono, H | 1 |
Fukuda, A | 1 |
Tabuse, H | 1 |
Ihara, N | 1 |
Tanabe, J | 1 |
Ikeda, H | 1 |
Kohama, A | 1 |
Bremer, AM | 1 |
Yamada, K | 1 |
West, CR | 1 |
Shiu, GK | 1 |
Nemoto, EM | 2 |
Nemmer, J | 1 |
Aldrete, JA | 2 |
Artru, AA | 1 |
Michenfelder, JD | 2 |
Taylor, CP | 4 |
Burke, SP | 1 |
Weber, ML | 2 |
Watson, GB | 1 |
Lanthorn, TH | 1 |
Imaizumi, S | 2 |
Kurosawa, K | 1 |
Kinouchi, H | 2 |
Yoshimoto, T | 7 |
Rataud, J | 1 |
Debarnot, F | 1 |
Mary, V | 1 |
Pratt, J | 1 |
Stutzmann, JM | 1 |
Cattaneo, AD | 1 |
Hayakawa, T | 1 |
Hamada, Y | 1 |
Maihara, T | 1 |
Hattori, H | 1 |
Mikawa, H | 1 |
Edmonds, HL | 1 |
Jiang, YD | 1 |
Zhang, PY | 1 |
Shank, RP | 1 |
Vartanian, MG | 2 |
Cordon, JJ | 2 |
Kupina, NC | 1 |
Schielke, GP | 1 |
Posner, A | 1 |
Raser, KJ | 1 |
Wang, KK | 1 |
Schnabel, R | 1 |
Rambeck, B | 1 |
May, T | 1 |
Jürgens, U | 1 |
Lahl, R | 1 |
Iwasaki, H | 1 |
Ohmachi, Y | 1 |
Takashima, K | 1 |
Tani, S | 1 |
Kasuya, H | 1 |
Shimizu, T | 1 |
Frantseva, MV | 1 |
Carlen, PL | 1 |
El-Beheiry, H | 1 |
Saito, Y | 1 |
Hashimoto, T | 1 |
Iwata, H | 1 |
Takahashi, K | 1 |
Fukumizu, M | 1 |
Sasaki, M | 1 |
Hanaoka, S | 1 |
Sugai, K | 1 |
D'Agostino, MD | 1 |
Andermann, F | 1 |
Dubeau, F | 1 |
Fedi, M | 1 |
Bastos, A | 1 |
Behringer, W | 1 |
Kentner, R | 1 |
Wu, X | 1 |
Tisherman, SA | 1 |
Radovsky, A | 1 |
Stezoski, WS | 1 |
Henchir, J | 1 |
Prueckner, S | 1 |
Safar, P | 1 |
Romo-Salas, F | 1 |
Jankovsky, L | 1 |
Franatovic, Y | 1 |
Qi, L | 1 |
Dong, W | 1 |
Mizoi, K | 5 |
Boxer, PA | 1 |
Mann, ME | 1 |
Rodolosi, LC | 1 |
Rock, DM | 1 |
Marcoux, FW | 1 |
Motomiya, M | 1 |
Amagasa, M | 2 |
Ogawa, A | 1 |
Magalini, SI | 1 |
Sabato, AF | 1 |
Pala, F | 1 |
Abiko, H | 2 |
Suzuki, J | 3 |
Oba, M | 2 |
Aitkenhead, A | 1 |
Heuser, D | 1 |
Guggenberger, H | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Lidocaine For Neuroprotection During Cardiac Surgery[NCT00938964] | 550 participants (Actual) | Interventional | 2009-07-31 | Completed | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
"Center for Epidemiological Studies Depression Scale (CES-D). The CES-D is a 20-item self-report examination designed to measure symptoms of depression. Subjects rate the degree to which they have experienced a range of symptoms of depression, such as I had crying spells and I felt lonely. Scores range from 0 to 60, with higher scores indicating greater depressive symptoms. Scores greater than 16 are typically considered indicative of clinically significant depression." (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -1.27 |
Placebo | -0.89 |
"Center for Epidemiological Studies Depression Scale (CES-D). The CES-D is a 20-item self-report examination designed to measure symptoms of depression. Subjects rate the degree to which they have experienced a range of symptoms of depression, such as I had crying spells and I felt lonely. Scores range from 0 to 60, with higher scores indicating greater depressive symptoms. Scores greater than 16 are typically considered indicative of clinically significant depression." (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.57 |
Placebo | 0.16 |
To characterize cognitive function over time, while minimizing potential redundancy in the cognitive measures, a factor analysis was performed on the 14 cognitive test scores from baseline. We chose a five-factor solution, which represents 5 cognitive domains: structured verbal memory, unstructured verbal memory, executive function, visual memory and attention/concentration. To quantify overall cognitive function, a baseline cognitive index was first calculated as the mean of the 5 preoperative domain scores. The cognitive index score has a mean of zero, thus any positive score is above the mean, any negative score is below the mean. A continuous change score was then calculated by subtracting the baseline from the 1 year cognitive index. The resulting outcome measure is unbounded with standard deviation of 0.35. A negative change score indicating decline and a positive score indicating improvement (NCT00938964)
Timeframe: 1 year after surgery
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.09 |
Placebo | 0.07 |
To characterize cognitive function over time, while minimizing potential redundancy in the cognitive measures, a factor analysis was performed on the 14 cognitive test scores from baseline. We chose a five-factor solution, which represents 5 cognitive domains: structured verbal memory, unstructured verbal memory, executive function, visual memory and attention/concentration. To quantify overall cognitive function, a baseline cognitive index was first calculated as the mean of the 5 preoperative domain scores. The cognitive index score has a mean of zero, thus any positive score is above the mean, any negative score is below the mean. A continuous change score was then calculated by subtracting the baseline from the 6-week cognitive index. The resulting outcome measure is unbounded with standard deviation of 0.35. A negative change score indicating decline and a positive score indicating improvement. (NCT00938964)
Timeframe: Preoperative to 6 weeks after surgery
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.07 |
Placebo | 0.07 |
"The DASI is a 12-item scale of functional capacity that has been found to correlate well with objective measures of maximal exercise capacity. Items reflect activities of personal care, ambulation, household tasks, sexual function, and recreational activities. Activities done with no difficulty receive scores, which are weighted and summed, for a quantitative measure of functional status. Scores range from 0 to 60; a higher-weighted score indicates better function." (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 6.3 |
Placebo | 6.96 |
"The DASI is a 12-item scale of functional capacity that has been found to correlate well with objective measures of maximal exercise capacity. Items reflect activities of personal care, ambulation, household tasks, sexual function, and recreational activities. Activities done with no difficulty receive scores, which are weighted and summed, for a quantitative measure of functional status. Scores range from 0 to 60; a higher-weighted score indicates better function." (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -10.98 |
Placebo | -11.67 |
The National Institutes of Health Stroke Scale (NIHSS) is a 15-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. A trained observer rates the patent's ability to answer questions and perform activities. Ratings for each item are scored with 3 to 5 grades with 0 as normal, and there is an allowance for untestable items. The range of scores is from 0 (normal) to 42 (profound effect of stroke on patient). (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.05 |
Placebo | 0.07 |
The National Institutes of Health Stroke Scale (NIHSS) is a 15-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. A trained observer rates the patent's ability to answer questions and perform activities. Ratings for each item are scored with 3 to 5 grades with 0 as normal, and there is an allowance for untestable items. The range of scores is from 0 (normal) to 42 (profound effect of stroke on patient). (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.05 |
Placebo | 0.04 |
The Western perioperative neurologic scale was designed to detect neurologic deficits after cardiac surgery. It includes 14 items classified into eight domains (mentation, speech, cranial nerve function, motor weakness, sensation and cerebellum, reflexes, and gait). Each item is scored from 0 (severe deficit) to3 (normal), and a maximum score of 42 indicates normal neurological function. (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.02 |
Placebo | -0.02 |
The Western perioperative neurologic scale was designed to detect neurologic deficits after cardiac surgery. It includes 14 items classified into eight domains (mentation, speech, cranial nerve function, motor weakness, sensation and cerebellum, reflexes, and gait). Each item is scored from 0 (severe deficit) to3 (normal), and a maximum score of 42 indicates normal neurological function. (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.04 |
Placebo | -0.01 |
"Perceived Social Support Scale: Twelve items indicate how strongly subjects agree that there is a special person who is around when I am in need and my family really tries to help me. Choices range from very strongly disagree to very strongly agree. Items are summed for a range of 12 to 84, with a high score meaning more social support." (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.71 |
Placebo | -1.16 |
"Perceived Social Support Scale: Twelve items indicate how strongly subjects agree that there is a special person who is around when I am in need and my family really tries to help me. Choices range from very strongly disagree to very strongly agree. Items are summed for a range of 12 to 84, with a high score meaning more social support." (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 1.23 |
Placebo | -0.49 |
"Social Activity: This measure consisted of eight items that indicate the degree of social interaction. Sample items are How often do you talk on the telephone with friends and relatives? and How often do you attend meetings of social groups, clubs, or civic organizations? Scores range from 8 to 32. A lower score indicates more social activity." (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -0.20 |
Placebo | 0.03 |
"Social Activity: This measure consisted of eight items that indicate the degree of social interaction. Sample items are How often do you talk on the telephone with friends and relatives? and How often do you attend meetings of social groups, clubs, or civic organizations? Scores range from 8 to 32. A lower score indicates more social activity." (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.95 |
Placebo | 1.59 |
"Spielberger State Anxiety Inventory (STAI): The STAI consists of two 20-item scales that measure anxiety. Representative items include statements such as I feel nervous and I feel worried. These items are rated on a 4-point scale, based on how well they describe the patient's current or typical mood, from not at all to very much so. Scores range from 20 to 80, with higher scores indicating greater anxiety." (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -6.70 |
Placebo | -6.39 |
"Spielberger State Anxiety Inventory (STAI): The STAI consists of two 20-item scales that measure anxiety. Representative items include statements such as I feel nervous and I feel worried. These items are rated on a 4-point scale, based on how well they describe the patient's current or typical mood, from not at all to very much so. Scores range from 20 to 80, with higher scores indicating greater anxiety." (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -7.12 |
Placebo | -6.31 |
Symptom limitations: Patients were given a list of eight symptoms and asked to rate the degree to which the symptom limited daily activities. The symptoms were angina, shortness of breath, arthritis, back trouble, leg pains, headaches, fatigue, and other. Scores range from 8 to 32, with higher scores indicating greater limitations. (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -1.39 |
Placebo | -1.48 |
Symptom limitations: Patients were given a list of eight symptoms and asked to rate the degree to which the symptom limited daily activities. The symptoms were angina, shortness of breath, arthritis, back trouble, leg pains, headaches, fatigue, and other. Scores range from 8 to 32, with higher scores indicating greater limitations. (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -0.67 |
Placebo | -0.8 |
"Cognitive Difficulties Scale: a 39-item scale, is a self-report assessment of perceived problems in long- and short-term memory, concentration, attention, and psycho-motor coordination. Sample items are I forget errands I planned to do and I fail to recognize people I know. Scores range from 39 to 164, with higher scores indicating greater cognitive difficulty." (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -0.46 |
Placebo | -1.02 |
"Cognitive Difficulties Scale: a 39-item scale, is a self-report assessment of perceived problems in long- and short-term memory, concentration, attention, and psycho-motor coordination. Sample items are I forget errands I planned to do and I fail to recognize people I know. Scores range from 39 to 164, with higher scores indicating greater cognitive difficulty." (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -3 |
Placebo | -3.21 |
"Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL): This measure contains six items that assess the ability to perform important tasks for daily living (e.g., Could you prepare your own meals? Could you drive a car?). Scores range from 6 to 24. Higher scores indicate increasing difficulty in engaging in daily activities." (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -0.15 |
Placebo | -0.31 |
"Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL): This measure contains six items that assess the ability to perform important tasks for daily living (e.g., Could you prepare your own meals? Could you drive a car?). Scores range from 6 to 24. Higher scores indicate increasing difficulty in engaging in daily activities." (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 2.46 |
Placebo | 2.1 |
To characterize cognitive function over time, while minimizing potential redundancy in the cognitive measures, a factor analysis was performed on the 14 cognitive test scores from baseline. We chose a five-factor solution, which represents 5 cognitive domains: structured verbal memory, unstructured verbal memory, executive function, visual memory and attention/concentration. Each domain score is normally distributed with a mean of zero. A change score was calculated for each domain by subtracting the baseline from the 6-week score. A dichotomous outcome variable of post-operative cognitive deficit was defined as a decline of ≥1 standard deviation in 1 or more of the 5 domains. (NCT00938964)
Timeframe: Preoperative to 6 weeks after surgery
Intervention | Participants (Count of Participants) |
---|---|
Lidocaine | 87 |
Placebo | 83 |
The Medical Outcomes Study 36-Item Short Form Health Survey (SF-36): The SF-36 was designed to measure general health status. Two scales were used: Work Activities (four items) and General Health (one item). For the work activities scale, the reported score was the sum of four questions, each with values ranging from 1 to 4, the total score could range from 4 to 16. A higher score on Work Activities indicates more health-related problems For the general health question, the patients ranked their health from Excellent (1) to poor (5), the scale ranged from 1 to 5 with 1 being best health and 5 being worst. A high score in General Health indicates poorer health state. (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) | |
---|---|---|
1 year Change Work Activities | 1 year Change General health perception | |
Lidocaine | -1.37 | -0.28 |
Placebo | -1.42 | -0.43 |
The Medical Outcomes Study 36-Item Short Form Health Survey (SF-36): The SF-36 was designed to measure general health status. Two scales were used: Work Activities (four items) and General Health (one item). For the work activities scale, the reported score was the sum of four questions, each with values ranging from 1 to 4, the total score could range from 4 to 16. A higher score on Work Activities indicates more health-related problems For the general health question, the patients ranked their health from Excellent (1) to poor (5), the scale ranged from 1 to 5 with 1 being best health and 5 being worst. A high score in General Health indicates poorer health state. (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) | |
---|---|---|
6-Week Change Work activities | 6-Week Change General health perception | |
Lidocaine | 2.71 | -0.004 |
Placebo | 3 | -0.03 |
Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removalime points and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups (NCT00938964)
Timeframe: Baseline to 6 hours post cross-clamp removal
Intervention | Mean linear fluorescence intensity-MLFI (Mean) | |||
---|---|---|---|---|
Baseline | Cross-clamp removal | End of Bypass | 6 hours post cross-clamp removal | |
Lidocaine | -0.15 | 0.02 | -0.73 | -0.10 |
Placebo | -0.43 | -0.73 | -0.40 | 0.19 |
Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removalime points and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups (NCT00938964)
Timeframe: Baseline to 6 hours post cross-clamp removal
Intervention | Mean linear fluorescence intensity-MLFI (Mean) | |||
---|---|---|---|---|
Baseline | Cross-clamp removal | End of Bypass | 6 hours post cross-clamp removal | |
Lidocaine | -4.22 | -2.46 | -0.34 | 1.21 |
Placebo | -0.04 | 1.83 | 2.64 | 0.54 |
Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removal and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups (NCT00938964)
Timeframe: Baseline to 6 hours post cross-clamp removal
Intervention | Mean linear fluorescence intensity-MLFI (Mean) | |||
---|---|---|---|---|
Baseline | Cross-clamp removal | End of Bypass | 6 hours post cross-clamp removal | |
Lidocaine | -2.02 | 0.56 | 0.58 | 1.04 |
Placebo | -0.08 | 0.17 | 1.19 | -0.68 |
Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removalime points and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups (NCT00938964)
Timeframe: Baseline to 6 hours post cross-clamp removal
Intervention | Mean linear fluorescence intensity-MLFI (Mean) | |||
---|---|---|---|---|
Baseline | Cross-clamp removal | End of Bypass | 6 hours post cross-clamp removal | |
Lidocaine | -0.03 | 0.03 | 0.33 | 0.37 |
Placebo | 0.35 | 0.43 | 0.05 | 0.27 |
5 reviews available for phenytoin and Cerebral Ischemia
Article | Year |
---|---|
Head injury (moderate to severe).
Topics: Acute Disease; Anticonvulsants; Brain Injuries; Brain Ischemia; Coma; Craniocerebral Trauma; Glasgow | 2010 |
Apneustic breathing in children with brainstem damage due to hypoxic-ischemic encephalopathy.
Topics: Brain; Brain Diseases; Brain Ischemia; Brain Stem; Child, Preschool; Dose-Response Relationship, Dru | 1999 |
[Cerebral protection].
Topics: Animals; Barbiturates; Brain Ischemia; Diuretics; Fatty Acids, Nonesterified; Humans; Hypothermia, I | 1986 |
Ionic changes in brain ischaemia and alterations produced by drugs.
Topics: Animals; Biological Transport, Active; Brain Ischemia; Calcium; Calcium Channel Blockers; Cats; Extr | 1985 |
Cerebral preservation for intraoperative focal ischemia.
Topics: Adenosine Triphosphate; Anesthesia; Anesthetics; Aneurysm; Animals; Barbiturates; Brain; Brain Disea | 1985 |
33 other studies available for phenytoin and Cerebral Ischemia
Article | Year |
---|---|
PHACES syndrome with moyamoya vasculopathy - a case report.
Topics: Anticonvulsants; Aortic Coarctation; Aspirin; Brain Ischemia; Child, Preschool; Eye Abnormalities; F | 2013 |
Incidence of delayed seizures, delayed cerebral ischemia and poor outcome with the use of levetiracetam versus phenytoin after aneurysmal subarachnoid hemorrhage.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticonvulsants; Brain Ischemia; Female; Follow-Up Stud | 2014 |
Phenytoin and carbamazepine delay the initial depression of the population spike upon exposure to in vitro ischemia and promote its post-ischemic functional recovery in rat hippocampal slices.
Topics: Animals; Anticonvulsants; Brain Ischemia; Carbamazepine; Electrophysiology; Glucose; Hippocampus; Hy | 2006 |
Effects of phenytoin on regional cerebral blood flow, electroencephalogram, and electrolyte contents in cerebral blood and cerebral cortex following total cerebral ischemia in dogs.
Topics: Animals; Brain Ischemia; Cerebral Cortex; Cerebrovascular Circulation; Dogs; Electroencephalography; | 1983 |
Ischemic cerebral edema in primates: effects of acetazolamide, phenytoin, sorbitol, dexamethasone, and methylprednisolone on brain water and electrolytes.
Topics: Acetazolamide; Animals; Brain; Brain Edema; Brain Ischemia; Cerebral Cortex; Dexamethasone; Haplorhi | 1980 |
Dose of thiopental, pentobarbital, and phenytoin for maximal therapeutic effects in cerebral ischemic anoxia.
Topics: Animals; Brain Chemistry; Brain Ischemia; Fatty Acids, Nonesterified; Female; Hypoxia, Brain; Ketami | 1983 |
Phenytoin in the treatment of cerebral ischemia.
Topics: Animals; Blood Pressure; Brain Ischemia; Cerebrovascular Circulation; Humans; Phenytoin; Rabbits | 1981 |
Phenytoin in the treatment of cerebral ischemia.
Topics: Animals; Blood Pressure; Brain Ischemia; Cardiac Output; Cerebrovascular Circulation; Dogs; Phenytoi | 1981 |
Hippocampal slices: glutamate overflow and cellular damage from ischemia are reduced by sodium-channel blockade.
Topics: Animals; Brain Ischemia; Electrophysiology; Glutamic Acid; Hippocampus; In Vitro Techniques; Phenyto | 1995 |
Phenytoin delays ischemic depolarization, but cannot block its long-term consequences, in the rat hippocampal slice.
Topics: Animals; Brain Ischemia; Disease Models, Animal; Dose-Response Relationship, Drug; Glucose; Hippocam | 1995 |
Effect of phenytoin on cortical Na(+)-K(+)-ATPase activity in global ischemic rat brain.
Topics: Animals; Body Water; Brain Ischemia; Cerebral Cortex; Male; Phenytoin; Potassium; Rats; Rats, Wistar | 1995 |
Damage from oxygen and glucose deprivation in hippocampal slices is prevented by tetrodotoxin, lidocaine and phenytoin without blockade of action potentials.
Topics: Action Potentials; Animals; Brain Ischemia; Evoked Potentials; Hippocampus; Hypoxia, Brain; In Vitro | 1994 |
Comparative study of voltage-sensitive sodium channel blockers in focal ischaemia and electric convulsions in rodents.
Topics: Animals; Anticonvulsants; Brain Ischemia; Carbamazepine; Cerebral Arteries; Electrophysiology; Elect | 1994 |
[Cerebral protection].
Topics: Adrenal Cortex Hormones; Anesthetics; Barbiturates; Benzodiazepines; Brain Ischemia; Calcium Channel | 1993 |
Phenytoin reduces neonatal hypoxic-ischemic brain damage in rats.
Topics: Animals; Animals, Newborn; Brain; Brain Ischemia; Cerebral Cortex; Cerebral Infarction; Corpus Stria | 1994 |
Anticonvulsant activity of topiramate and phenytoin in a rat model of ischemia-induced epilepsy.
Topics: Acoustic Stimulation; Animals; Anticonvulsants; Brain Ischemia; Epilepsy; Fructose; Male; Phenytoin; | 1996 |
Phenytoin pretreatment prevents hypoxic-ischemic brain damage in neonatal rats.
Topics: Animals; Animals, Newborn; Anticonvulsants; Body Temperature Regulation; Brain Damage, Chronic; Brai | 1996 |
Relationship between ischemic damage and concentrations of phenytoin and phenobarbital in the brain cortex of epileptic patients in vegetative state at death.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Autopsy; Brain Ischemia; Case-Control Studies; Cere | 1996 |
Optimal dose for barbiturate protection of the ischemic brain.
Topics: Animals; Anticonvulsants; Barbiturates; Brain Ischemia; Dose-Response Relationship, Drug; Humans; Ph | 1996 |
Phenytoin-induced cerebral thrombosis in rats: cerebral ultrastructure, water content and ischaemic volume in the acute phase.
Topics: Acute Disease; Animals; Arteries; Brain Edema; Brain Ischemia; Cerebral Cortex; Disease Models, Anim | 1996 |
A submersion method to induce hypoxic damage in organotypic hippocampal cultures.
Topics: Animals; Brain Ischemia; Cell Death; Cell Hypoxia; Culture Media; Electric Stimulation; Hippocampus; | 1999 |
Exceptionally long absence status: multifactorial etiology, drug interactions and complications.
Topics: Aged; Anticonvulsants; Brain Ischemia; Dementia, Vascular; Drug Interactions; Epilepsy, Generalized; | 1999 |
Thiopental and phenytoin by aortic arch flush for cerebral preservation during exsanguination cardiac arrest of 20 minutes in dogs. An exploratory study.
Topics: Animals; Anticonvulsants; Aorta, Thoracic; Brain Ischemia; Cardiopulmonary Resuscitation; Cerebrovas | 2001 |
Effect of pretreatment with thiopental and phenytoin on postischemic brain damage in rabbits.
Topics: Animals; Brain Ischemia; Hypoxia, Brain; Phenytoin; Placebos; Rabbits; Thiopental | 1979 |
[Protective action of phenytoin on cerebral ischemia in rats].
Topics: Animals; Brain Ischemia; Calcium-Transporting ATPases; Electroencephalography; Female; Male; Phenyto | 1992 |
Intraoperative monitoring of the somatosensory evoked potentials and cerebral blood flow during aneurysm surgery--safety evaluation for temporary vascular occlusion.
Topics: Brain Ischemia; Cerebrovascular Circulation; Drug Combinations; Evoked Potentials, Somatosensory; Hu | 1991 |
Comparison of phenytoin with noncompetitive N-methyl-D-aspartate antagonists in a model of focal brain ischemia in rat.
Topics: Animals; Brain Ischemia; Disease Models, Animal; Dizocilpine Maleate; Male; N-Methylaspartate; Phenc | 1990 |
Phenytoin affects metabolism of free fatty acids and nucleotides in rat cerebral ischemia.
Topics: Animals; Brain Ischemia; Cytidine Triphosphate; Energy Metabolism; Fatty Acids, Nonesterified; Male; | 1990 |
Actions of brain-protecting substances against both oxygen and glucose deprivation in the guinea pig hippocampal neurons studied in vitro.
Topics: Action Potentials; Animals; Brain Ischemia; Electric Stimulation; Glucose; Guinea Pigs; Hippocampus; | 1989 |
[Protective effect of phenytoin and its enhanced action by combined administration of mannitol and vitamin E in cerebral ischemia].
Topics: Animals; Brain Edema; Brain Ischemia; Dogs; Drug Synergism; Electroencephalography; Injections, Intr | 1986 |
Protective effect of phenytoin and its enhanced action by combined administration with mannitol and vitamin E in cerebral ischaemia.
Topics: Animals; Brain Edema; Brain Ischemia; Dogs; Drug Therapy, Combination; Electroencephalography; Evans | 1987 |
[Protective effect of various agents against ischemic neuronal damage in guinea pig hippocampal neurons studied in vitro].
Topics: Animals; Brain Ischemia; Dexamethasone; Guinea Pigs; Hippocampus; In Vitro Techniques; Mannitol; Mic | 1988 |
Cerebral protection.
Topics: Adrenal Cortex Hormones; Barbiturates; Blood Glucose; Brain Edema; Brain Ischemia; Calcium Channel B | 1986 |